176 related articles for article (PubMed ID: 21843643)
21. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
22. An Insilico evaluation of phytocompounds from Albizia amara and Phyla nodiflora as cyclooxygenase-2 enzyme inhibitors.
Loganathan Y; Jain M; Thiyagarajan S; Shanmuganathan S; Mariappan SK; Kizhakedathil MPJ; Saravanakumar T
Daru; 2021 Dec; 29(2):311-320. PubMed ID: 34415547
[TBL] [Abstract][Full Text] [Related]
23. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398.
Rioux N; Castonguay A
Cancer Res; 1998 Dec; 58(23):5354-60. PubMed ID: 9850065
[TBL] [Abstract][Full Text] [Related]
24. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429
[TBL] [Abstract][Full Text] [Related]
25. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT
Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146
[TBL] [Abstract][Full Text] [Related]
26. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
Xu H; Izon DJ; Loftin C; Spain LM
Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
[TBL] [Abstract][Full Text] [Related]
27. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
28. On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1.
Burde T; Rimon G
Eur J Pharmacol; 2002 Oct; 453(2-3):167-73. PubMed ID: 12398900
[TBL] [Abstract][Full Text] [Related]
29. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
30. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
Rowlinson SW; Kiefer JR; Prusakiewicz JJ; Pawlitz JL; Kozak KR; Kalgutkar AS; Stallings WC; Kurumbail RG; Marnett LJ
J Biol Chem; 2003 Nov; 278(46):45763-9. PubMed ID: 12925531
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cyclooxygenase-2 with NS-398 and the prevention of radiation-induced transformation, micronuclei formation and clonogenic cell death in C3H 10T1/2 cells.
Bisht KS; Bradbury CM; Zoberi I; Curry HA; Kaushal A; Roti Roti JL; Gius D
Int J Radiat Biol; 2003 Nov; 79(11):879-88. PubMed ID: 14698956
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
33. Binding of indomethacin methyl ester to cyclooxygenase-2. A computational study.
Sárosi MB
J Mol Model; 2018 Jun; 24(7):150. PubMed ID: 29869728
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts.
Castaño E; Bartrons R; Gil J
J Pharmacol Exp Ther; 2000 May; 293(2):509-13. PubMed ID: 10773022
[TBL] [Abstract][Full Text] [Related]
35. Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.
Pouplana R; Lozano JJ; Pérez C; Ruiz J
J Comput Aided Mol Des; 2002 Oct; 16(10):683-709. PubMed ID: 12650588
[TBL] [Abstract][Full Text] [Related]
36. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity.
Rosenstock M; Danon A; Rimon G
Biochim Biophys Acta; 1999 Aug; 1440(1):127-37. PubMed ID: 10477832
[TBL] [Abstract][Full Text] [Related]
37. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.
Al-Suwaidan IA; Alanazi AM; El-Azab AS; Al-Obaid AM; ElTahir KE; Maarouf AR; Abu El-Enin MA; Abdel-Aziz AA
Bioorg Med Chem Lett; 2013 May; 23(9):2601-5. PubMed ID: 23528298
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo.
Futaki N; Takahashi S; Kitagawa T; Yamakawa Y; Tanaka M; Higuchi S
Inflamm Res; 1997 Dec; 46(12):496-502. PubMed ID: 9459080
[TBL] [Abstract][Full Text] [Related]
39. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
Ermondi G; Caron G; Lawrence R; Longo D
J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061
[TBL] [Abstract][Full Text] [Related]
40. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
